Anton Alexander Nolte Peterlin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anton Alexander Nolte Peterlin has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Louise Kruse Jensen
University of Copenhagen, Department of Veterinary and Animal Sciences, Copenhagen, Denmark
6 shared publicationsHans Gottlieb
Department of Orthopedic Surgery, Herlev and Gentofte Hospital, Herlev, Denmark
4 shared publications- Hans Gottlieb
Department of Orthopedic Surgery, Herlev Hospital, 2730 Herlev, Denmark
4 shared publications Ann Jørgensen
Department of Orthopedic Surgery, Herlev and Gentofte Hospital, Herlev, Denmark
3 shared publicationsInger Brock
Department of Microbiology, Herlev Hospital, Herlev, Denmark
3 shared publications- Martin McNally
The Bone Infection Unit, Nuffield Orthopaedic Centre, Oxford University Hospitals, Oxford, United Kingdom
3 shared publications
Latest Publications
- 6 November 2026
- Published by British Editorial Society of Bone & Joint Surgery in Orthopaedic Proceedings
- Vol. 108-B (SUPP_11) , 76
RETHINKING BACTERIAL OSTEOLYSIS: EVIDENCE BEYOND THE RANKL PARADIGM
Background: Bone and joint infections (BJIs) are debilitating conditions characterized by intraosseous bacteria, biofilm formation, suppurative inflammation, and osteolysis. Bacteria-associated bone loss is traditionally attributed to RANKL-mediated osteoclast activation, largely based on in vitro and murine studies. However, emerging translational evidence from large-animal models and clinical studies suggests that this paradigm may not fully explain bacteria-associated osteolysis. Methods: The translational study applied a porcine implant-associated osteomyelitis (IAO) model and patients with fracture-related infection (FRI) to investigate pathophysiological mechanisms of infectious osteolysis. RANKL signalling was inhibited using Denosumab in vivo, and bone loss was assessed by CT and histology, while osteoclast activity was assessed by immunohistochemistry and qPCR. The FRI patients were categorized as osteolytic (n =14) and non-osteolytic (n =7) based on CT scans. Biopsies collected at revision surgery were assessed by histology to quantify osteoclast numbers and by mRNA in situ hybridization to quantify RANKL, MMP1, and C3 expression. Results: In the IAO model, RANKL inhibition with Denosumab did not reduce radiographic osteolysis compared to infected controls; CT-defined bone loss was even increased in treated animals (1.25 vs. 0.63 cm 3 , p=0.005) despite a marked reduction in osteoclast numbers. Furthermore, local RANKL expression did not correlate with bone loss. In FRI patients, osteoclast numbers were not associated with osteolysis severity (ρ=0.34, p=0.21). In contrast, MMP1 expression was significantly increased in patients with osteolytic lesions, whereas RANKL expression remained unchanged between osteolytic and non-osteolytic groups. Spatial analyses demonstrated heterogeneous expression of MMP1 and RANKL, in contrast to uniform C3 expression. Osteolysis severity correlated with MMP1 spatial burden (ρ=0.74, p=0.011). Discussion: These findings shows that bacterial-associated osteolysis is not primarily driven by RANKL-mediated osteoclastogenesis but is a multifactorial process shaped by inflammation, proteolysis, neutrophil responses, and impaired osteogenesis. This challenges the prevailing RANKL paradigm and supports a broader osteoimmunological model, or conceptualization, of infectious bone loss.
- 6 November 2026
- Published by British Editorial Society of Bone & Joint Surgery in Orthopaedic Proceedings
- Vol. 108-B (SUPP_11) , 76
RETHINKING BACTERIAL OSTEOLYSIS: EVIDENCE BEYOND THE RANKL PARADIGM
Background: Bone and joint infections (BJIs) are debilitating conditions characterized by intraosseous bacteria, biofilm formation, suppurative inflammation, and osteolysis. Bacteria-associated bone loss is traditionally attributed to RANKL-mediated osteoclast activation, largely based on in vitro and murine studies. However, emerging translational evidence from large-animal models and clinical studies suggests that this paradigm may not fully explain bacteria-associated osteolysis. Methods: The translational study applied a porcine implant-associated osteomyelitis (IAO) model and patients with fracture-related infection (FRI) to investigate pathophysiological mechanisms of infectious osteolysis. RANKL signalling was inhibited using Denosumab in vivo, and bone loss was assessed by CT and histology, while osteoclast activity was assessed by immunohistochemistry and qPCR. The FRI patients were categorized as osteolytic (n =14) and non-osteolytic (n =7) based on CT scans. Biopsies collected at revision surgery were assessed by histology to quantify osteoclast numbers and by mRNA in situ hybridization to quantify RANKL, MMP1, and C3 expression. Results: In the IAO model, RANKL inhibition with Denosumab did not reduce radiographic osteolysis compared to infected controls; CT-defined bone loss was even increased in treated animals (1.25 vs. 0.63 cm 3 , p=0.005) despite a marked reduction in osteoclast numbers. Furthermore, local RANKL expression did not correlate with bone loss. In FRI patients, osteoclast numbers were not associated with osteolysis severity (ρ=0.34, p=0.21). In contrast, MMP1 expression was significantly increased in patients with osteolytic lesions, whereas RANKL expression remained unchanged between osteolytic and non-osteolytic groups. Spatial analyses demonstrated heterogeneous expression of MMP1 and RANKL, in contrast to uniform C3 expression. Osteolysis severity correlated with MMP1 spatial burden (ρ=0.74, p=0.011). Discussion: These findings shows that bacterial-associated osteolysis is not primarily driven by RANKL-mediated osteoclastogenesis but is a multifactorial process shaped by inflammation, proteolysis, neutrophil responses, and impaired osteogenesis. This challenges the prevailing RANKL paradigm and supports a broader osteoimmunological model, or conceptualization, of infectious bone loss.
- 6 November 2026
- Published by British Editorial Society of Bone & Joint Surgery in Orthopaedic Proceedings
- Vol. 108-B (SUPP_11) , 40
DO PAIRED MICROBIOLOGY AND HISTOLOGY HAVE A PLACE IN CHRONIC OSTEOMYELITIS AND FRACTURE-RELATED INFECTIONS?
Background: Microbiological culture and histology are independent diagnostic criteria in chronic osteomyelitis (cOM) and fracture-related infection (FRI). However, the prognostic value of combining these modalities within the same tissue sample has rarely been investigated. Therefore, this study examined whether paired microbiological and histological assessments could provide additional insight into disease severity. We hypothesized that increased numbers of neutrophils and osteoclasts would be associated with culture-positive samples, and that samples positive on both microbiology and histology would reflect more severe disease. Methods: In this prospective single-centre study, adults undergoing surgery for confirmed FRI or cOM were included. Clinical and disease classification data (FRI and BACH) were recorded. Five deep-tissue samples were collected intraoperatively and divided for microbiological culture and histological assessment of osteoclasts and neutrophil infiltration. Histological positivity was defined as having more than 5 neutrophils per high-power field (x400) in accordance with international diagnostic guidelines. Microbiological positivity was defined as a positive culture. Microbiological diagnostic confirmation of infection in the individual patient was defined by isolating phenotypically indistinguishable pathogens from at least 2/5 separate samples. Results: Forty-one patients were included (11 cOM, 30 FRI), of whom 68% received preoperative antibiotics. Over 60% of patients in the cohort had poorly controlled comorbidities. Nineteen patients (46%) were diagnosed as culture-positive, while 32 patients (78%) were histologically positive. Among the 205 samples (5 from each patient), 31% were culture-positive, 56% histology-positive, and 26% double-positive. Histological scores were significantly higher in culture-positive samples (p <0.001). Treatment failure occurred in seven patients (18%), all with FRI. Paired positive samples were associated with increased odds of clinical failure and earlier revision, with odds increasing 1.68-fold for each additional paired positive sample (95% CI, 1.10–2.77). The distribution of osteoclasts did not differ substantially between culture-negative and positive samples (p = 0.23). Conclusions: The paired analysis demonstrated a strong concordance between culture positivity and suppurative inflammation within the same sample. Combining microbiology and histology may help identify patients at increased risk of revision, although larger studies are needed. The present study indicates that when a viable bacterium induces an inflammatory response, there is a greater risk of non-osteoclast-based tissue breakdown, destruction, or liquefaction, and thus a greater risk of local bacterial dispersion or hiding, which may facilitate mis-removal during debridement and antibiotic therapy, leading to increased risk of relapse.
- 6 November 2026
- Published by British Editorial Society of Bone & Joint Surgery in Orthopaedic Proceedings
- Vol. 108-B (SUPP_11) , 40
DO PAIRED MICROBIOLOGY AND HISTOLOGY HAVE A PLACE IN CHRONIC OSTEOMYELITIS AND FRACTURE-RELATED INFECTIONS?
Background: Microbiological culture and histology are independent diagnostic criteria in chronic osteomyelitis (cOM) and fracture-related infection (FRI). However, the prognostic value of combining these modalities within the same tissue sample has rarely been investigated. Therefore, this study examined whether paired microbiological and histological assessments could provide additional insight into disease severity. We hypothesized that increased numbers of neutrophils and osteoclasts would be associated with culture-positive samples, and that samples positive on both microbiology and histology would reflect more severe disease. Methods: In this prospective single-centre study, adults undergoing surgery for confirmed FRI or cOM were included. Clinical and disease classification data (FRI and BACH) were recorded. Five deep-tissue samples were collected intraoperatively and divided for microbiological culture and histological assessment of osteoclasts and neutrophil infiltration. Histological positivity was defined as having more than 5 neutrophils per high-power field (x400) in accordance with international diagnostic guidelines. Microbiological positivity was defined as a positive culture. Microbiological diagnostic confirmation of infection in the individual patient was defined by isolating phenotypically indistinguishable pathogens from at least 2/5 separate samples. Results: Forty-one patients were included (11 cOM, 30 FRI), of whom 68% received preoperative antibiotics. Over 60% of patients in the cohort had poorly controlled comorbidities. Nineteen patients (46%) were diagnosed as culture-positive, while 32 patients (78%) were histologically positive. Among the 205 samples (5 from each patient), 31% were culture-positive, 56% histology-positive, and 26% double-positive. Histological scores were significantly higher in culture-positive samples (p <0.001). Treatment failure occurred in seven patients (18%), all with FRI. Paired positive samples were associated with increased odds of clinical failure and earlier revision, with odds increasing 1.68-fold for each additional paired positive sample (95% CI, 1.10–2.77). The distribution of osteoclasts did not differ substantially between culture-negative and positive samples (p = 0.23). Conclusions: The paired analysis demonstrated a strong concordance between culture positivity and suppurative inflammation within the same sample. Combining microbiology and histology may help identify patients at increased risk of revision, although larger studies are needed. The present study indicates that when a viable bacterium induces an inflammatory response, there is a greater risk of non-osteoclast-based tissue breakdown, destruction, or liquefaction, and thus a greater risk of local bacterial dispersion or hiding, which may facilitate mis-removal during debridement and antibiotic therapy, leading to increased risk of relapse.
- Open Access
- 18 June 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (6) , 620
Impact of Narrow Empiric Antibiotic Spectrum and Patient Characteristics on Clinical Outcomes in Bone and Joint Infections: A Retrospective Cohort Study
Background: Bone and joint infections (BJIs) are a significant clinical challenge due to their tendency to recur, increased healthcare expenses, reduced quality of life, and mortality. Patients with BJIs are a heterogeneous group due to their different clinical presentations as well as patient-related risk factors. Empiric antibiotic regimens are commonly based on deductions from in vitro microbiologic findings, despite the fact that their relative efficacy and optimal antibiotic choices are underexplored. Methods: This retrospective cohort study included 521 patients surgically treated for BJIs at a specialized orthopedic infection unit between 2016 and 2023. Treatment strategies were guided by the Oral Versus Intravenous Antibiotics for Bone and Joint Infection (OVIVA) trial. All patients received a narrow-spectrum Gram-positive–targeted empiric systemic antibiotic regimen determined according to regional recommendations in collaboration with infectious disease specialists. The primary outcome was clinical failure within one year, with a minimum follow-up of 12 months. For the analyses, the patients were divided into three groups based on microbiological susceptibility: susceptible (SusEmp), non-susceptible (NonSus) and culture-negative (CulNeg) patients. Results: The three groups were found to differ significantly in seven patient-related factors: sex, age at primary operation (OP age), BMI, ASA group, diabetes status, peripheral arterial disease status (PAD), and endocrinopathy status (other than diabetes). In performing multivariate analyses, OP age was found to be independently associated with the overall failure rate (p = 0.04) and ASA group (p = 0.047), and PAD (p = 0.043) was independently associated with the secondary outcome of proximal amputation. Patients with non-susceptible pathogens (NonSus) had more than twice the odds of clinical failure (OR: 2.10; 95% CI: 1.12–3.95) and nearly fivefold higher odds of secondary proximal amputation (OR: 4.95; 95% CI: 1.41–23.2) compared with patients with susceptible pathogens (SusEmp). Conclusions: The current study demonstrates that a large group of patients can presumably be treated safely with a more restrictive narrow approach. More studies are needed to identify subgroups suited for the safe use of a narrow-spectrum empiric regimen, hereby reserving the broad-spectrum antibiotics for patients with the right indications and for whom it would have a positive effect on the clinical outcome. Such an approach would justify a more restrictive stewardship of broad-spectrum antibiotic use without negatively impacting patient outcomes.
- 18 June 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (6) , 620
Open AccessImpact of Narrow Empiric Antibiotic Spectrum and Patient Characteristics on Clinical Outcomes in Bone and Joint Infections: A Retrospective Cohort Study
Background: Bone and joint infections (BJIs) are a significant clinical challenge due to their tendency to recur, increased healthcare expenses, reduced quality of life, and mortality. Patients with BJIs are a heterogeneous group due to their different clinical presentations as well as patient-related risk factors. Empiric antibiotic regimens are commonly based on deductions from in vitro microbiologic findings, despite the fact that their relative efficacy and optimal antibiotic choices are underexplored. Methods: This retrospective cohort study included 521 patients surgically treated for BJIs at a specialized orthopedic infection unit between 2016 and 2023. Treatment strategies were guided by the Oral Versus Intravenous Antibiotics for Bone and Joint Infection (OVIVA) trial. All patients received a narrow-spectrum Gram-positive–targeted empiric systemic antibiotic regimen determined according to regional recommendations in collaboration with infectious disease specialists. The primary outcome was clinical failure within one year, with a minimum follow-up of 12 months. For the analyses, the patients were divided into three groups based on microbiological susceptibility: susceptible (SusEmp), non-susceptible (NonSus) and culture-negative (CulNeg) patients. Results: The three groups were found to differ significantly in seven patient-related factors: sex, age at primary operation (OP age), BMI, ASA group, diabetes status, peripheral arterial disease status (PAD), and endocrinopathy status (other than diabetes). In performing multivariate analyses, OP age was found to be independently associated with the overall failure rate (p = 0.04) and ASA group (p = 0.047), and PAD (p = 0.043) was independently associated with the secondary outcome of proximal amputation. Patients with non-susceptible pathogens (NonSus) had more than twice the odds of clinical failure (OR: 2.10; 95% CI: 1.12–3.95) and nearly fivefold higher odds of secondary proximal amputation (OR: 4.95; 95% CI: 1.41–23.2) compared with patients with susceptible pathogens (SusEmp). Conclusions: The current study demonstrates that a large group of patients can presumably be treated safely with a more restrictive narrow approach. More studies are needed to identify subgroups suited for the safe use of a narrow-spectrum empiric regimen, hereby reserving the broad-spectrum antibiotics for patients with the right indications and for whom it would have a positive effect on the clinical outcome. Such an approach would justify a more restrictive stewardship of broad-spectrum antibiotic use without negatively impacting patient outcomes.
- Open Access
Clinical Outcome After Surgery for Fracture-Related Infection Is Dependent on Both Microbiology and the Host Inflammatory Response
Microbiological culture and histology of deep tissue specimens are independent diagnostic criteria in fracture-related infection (FRI). However, the association between these tests has rarely been investigated, particularly in relation to clinical outcome after treatment. Patients undergoing surgery for International Consensus-confirmed FRI were included. All had ≥5 tissue specimens taken for microbiological culture and 2–3 for histology. The correlation between cultured pathogen, histological positivity (defined as ≥5 polymorphonuclear neutrophils/high power field), and outcome at one year after surgery was explored. FRI was confirmed in 430 patients, predominantly in the tibia (194), femur (111), upper limb (70), and ankle (40). A total of 321 (74.7%) were culture-positive and 334 (77.7%) were histology positive, while 265 (61.6%) were positive for both tests. Staphylococcus aureus was cultured in 169 (42.5%), coagulase-negative Staphylococci (CoNS) in 61 (15.3%), and Gram-negatives in 145 (36.3%) cases. Virulent microorganisms were strongly associated with positive histology (odds ratio 2.72; 95% CI 1.61–4.58) but not with clinical failure (OR 1.08; 0.42–2.75). Isolation of S. aureus was significantly associated with positive histology compared to other microorganisms (OR 2.21; 1.27–3.87). Surgery succeeded in 390 (90.7%) patients. Treatment failure was weakly associated with positive microbiology alone (OR 2.03; 0.83–4.96) or positive histology alone (OR 2.13; 0.81–5.6). Combined positive culture and histology was strongly associated with clinical failure (OR 2.3; 1.06–4.96). There was no difference in outcome between virulent and non-virulent bacteria when histology was positive, but both had higher failure rates compared to patients with negative culture or histology. A pronounced inflammatory response, as seen in histology, is a feature of virulent bacterial FRI. However, the presence of virulent infection alone does not dictate clinical outcome without marked inflammation. This suggests that outcome is at least as much related to the host response as to the bacterium. When the pathological response is prominent, this may lead to tissue necrosis, further bacterial invasion of adjacent tissues, osteolysis and loss of fracture stability, contributing to treatment failure. This deserves further study to understand the mechanisms behind this interplay and clinical outcome.
Open AccessClinical Outcome After Surgery for Fracture-Related Infection Is Dependent on Both Microbiology and the Host Inflammatory Response
Microbiological culture and histology of deep tissue specimens are independent diagnostic criteria in fracture-related infection (FRI). However, the association between these tests has rarely been investigated, particularly in relation to clinical outcome after treatment. Patients undergoing surgery for International Consensus-confirmed FRI were included. All had ≥5 tissue specimens taken for microbiological culture and 2–3 for histology. The correlation between cultured pathogen, histological positivity (defined as ≥5 polymorphonuclear neutrophils/high power field), and outcome at one year after surgery was explored. FRI was confirmed in 430 patients, predominantly in the tibia (194), femur (111), upper limb (70), and ankle (40). A total of 321 (74.7%) were culture-positive and 334 (77.7%) were histology positive, while 265 (61.6%) were positive for both tests. Staphylococcus aureus was cultured in 169 (42.5%), coagulase-negative Staphylococci (CoNS) in 61 (15.3%), and Gram-negatives in 145 (36.3%) cases. Virulent microorganisms were strongly associated with positive histology (odds ratio 2.72; 95% CI 1.61–4.58) but not with clinical failure (OR 1.08; 0.42–2.75). Isolation of S. aureus was significantly associated with positive histology compared to other microorganisms (OR 2.21; 1.27–3.87). Surgery succeeded in 390 (90.7%) patients. Treatment failure was weakly associated with positive microbiology alone (OR 2.03; 0.83–4.96) or positive histology alone (OR 2.13; 0.81–5.6). Combined positive culture and histology was strongly associated with clinical failure (OR 2.3; 1.06–4.96). There was no difference in outcome between virulent and non-virulent bacteria when histology was positive, but both had higher failure rates compared to patients with negative culture or histology. A pronounced inflammatory response, as seen in histology, is a feature of virulent bacterial FRI. However, the presence of virulent infection alone does not dictate clinical outcome without marked inflammation. This suggests that outcome is at least as much related to the host response as to the bacterium. When the pathological response is prominent, this may lead to tissue necrosis, further bacterial invasion of adjacent tissues, osteolysis and loss of fracture stability, contributing to treatment failure. This deserves further study to understand the mechanisms behind this interplay and clinical outcome.
- Open Access
Rethinking Bacterial Osteolysis: Translational Evidence From a Porcine Model and Fracture‐Related Infections
Bone and joint infections (BJIs) are debilitating conditions that reduce quality of life. Key features include interosseous bacteria, biofilm formation, suppurative inflammation, and osteolysis. Traditionally, bacteria‐associated osteolysis has been attributed to RANKL‐mediated osteoclast activation, based largely on in vitro and murine studies, but emerging evidence challenges this view. In this translational study, a porcine implant‐associated osteomyelitis (IAO) model was combined with clinical fracture‐related infection (FRI) data to investigate mechanisms of bone loss. In the IAO model, RANKL signaling was inhibited using Denosumab, yet pathological and radiographic osteolysis remained unchanged. Local RANKL mRNA expression and active osteoclast numbers also did not correlate with bone destruction. In FRI patients, mRNA in situ hybridization showed that MMP1 expression was higher in osteolytic cases compared to non‐osteolytic ones, whereas RANKL expression did not differ. The technique revealed heterogeneous expression of MMP1 and RANKL , in contrast to uniform C3 expression. The number of active osteoclasts likewise did not correlate with osteolysis severity, and a patient with chronic osteomyelitis receiving Denosumab for osteoporosis still experienced extensive bone loss. These findings do not refute the RANKL–osteoclast pathway but indicate that bacteria‐associated osteolysis is multifactorial, shaped by inflammatory and osteoimmunological interactions, proteolysis, neutrophil activity, and impaired osteogenesis.
Open AccessRethinking Bacterial Osteolysis: Translational Evidence From a Porcine Model and Fracture‐Related Infections
Bone and joint infections (BJIs) are debilitating conditions that reduce quality of life. Key features include interosseous bacteria, biofilm formation, suppurative inflammation, and osteolysis. Traditionally, bacteria‐associated osteolysis has been attributed to RANKL‐mediated osteoclast activation, based largely on in vitro and murine studies, but emerging evidence challenges this view. In this translational study, a porcine implant‐associated osteomyelitis (IAO) model was combined with clinical fracture‐related infection (FRI) data to investigate mechanisms of bone loss. In the IAO model, RANKL signaling was inhibited using Denosumab, yet pathological and radiographic osteolysis remained unchanged. Local RANKL mRNA expression and active osteoclast numbers also did not correlate with bone destruction. In FRI patients, mRNA in situ hybridization showed that MMP1 expression was higher in osteolytic cases compared to non‐osteolytic ones, whereas RANKL expression did not differ. The technique revealed heterogeneous expression of MMP1 and RANKL , in contrast to uniform C3 expression. The number of active osteoclasts likewise did not correlate with osteolysis severity, and a patient with chronic osteomyelitis receiving Denosumab for osteoporosis still experienced extensive bone loss. These findings do not refute the RANKL–osteoclast pathway but indicate that bacteria‐associated osteolysis is multifactorial, shaped by inflammatory and osteoimmunological interactions, proteolysis, neutrophil activity, and impaired osteogenesis.
- Open Access
- 16 December 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (12) , 1277
Exploring the Value of Paired Microbiology and Histology in Chronic Osteomyelitis and Fracture-Related Infections
Background: Microbiological culture and histology are gold standards for diagnosing chronic osteomyelitis (cOM) and fracture-related infection (FRI). This study investigated whether combining these modalities within a single tissue sample provides additional insight into disease severity. We hypothesized that high neutrophil and osteoclast numbers correlate with culture-positive microbiology and that double-positive samples may indicate more severe disease. Methods: In this prospective single-centre study, adults undergoing surgery for confirmed FRI or cOM were included. Clinical and disease classification data (FRI and BACH) were recorded. Five deep-tissue samples were collected intraoperatively and divided for paired microbiological culture and histological assessment of neutrophil infiltration, according to international diagnostic guidelines. Results: Forty-one patients were included (11 cOM, 30 FRI) of whom 68% received preoperative antibiotics. Nineteen patients (46%) were identified as culture-positive, while 32 patients (78%) were histologically positive according to international diagnostic guidelines, respectively. Among the 205 samples, 31% were culture-positive, 56% histology-positive, and 26% double-positive. Histological scores were significantly higher in culture-positive samples (p < 0.001). Treatment failure occurred in seven patients (18%), all with FRI. Paired positive samples were associated with increased odds of clinical failure and earlier revision, with odds increasing 1.68-fold for each additional paired positive sample (95% CI, 1.10–2.77). Conclusions: The paired analysis demonstrated a strong concordance between culture-positivity and suppurative inflammation within the same sample. Combining microbiology and histology may help identify patients at increased risk of revision and enhance diagnostic certainty, particularly in patients identified as culture-negative.
- 16 December 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (12) , 1277
Open AccessExploring the Value of Paired Microbiology and Histology in Chronic Osteomyelitis and Fracture-Related Infections
Background: Microbiological culture and histology are gold standards for diagnosing chronic osteomyelitis (cOM) and fracture-related infection (FRI). This study investigated whether combining these modalities within a single tissue sample provides additional insight into disease severity. We hypothesized that high neutrophil and osteoclast numbers correlate with culture-positive microbiology and that double-positive samples may indicate more severe disease. Methods: In this prospective single-centre study, adults undergoing surgery for confirmed FRI or cOM were included. Clinical and disease classification data (FRI and BACH) were recorded. Five deep-tissue samples were collected intraoperatively and divided for paired microbiological culture and histological assessment of neutrophil infiltration, according to international diagnostic guidelines. Results: Forty-one patients were included (11 cOM, 30 FRI) of whom 68% received preoperative antibiotics. Nineteen patients (46%) were identified as culture-positive, while 32 patients (78%) were histologically positive according to international diagnostic guidelines, respectively. Among the 205 samples, 31% were culture-positive, 56% histology-positive, and 26% double-positive. Histological scores were significantly higher in culture-positive samples (p < 0.001). Treatment failure occurred in seven patients (18%), all with FRI. Paired positive samples were associated with increased odds of clinical failure and earlier revision, with odds increasing 1.68-fold for each additional paired positive sample (95% CI, 1.10–2.77). Conclusions: The paired analysis demonstrated a strong concordance between culture-positivity and suppurative inflammation within the same sample. Combining microbiology and histology may help identify patients at increased risk of revision and enhance diagnostic certainty, particularly in patients identified as culture-negative.
- Open Access
- 20 November 2025
- Published by Elsevier in Materialia
- Vol. 44
Gentamicin-loaded xerogel coating prevents peri‑prosthetic joint infection in an adult Göttingen minipig model
- 20 November 2025
- Published by Elsevier in Materialia
- Vol. 44
Open AccessGentamicin-loaded xerogel coating prevents peri‑prosthetic joint infection in an adult Göttingen minipig model
- Open Access
- 16 June 2025
- Published by Copernicus GmbH in Journal of Bone and Joint Infection
- Vol. 10 (3) , 199-206
CLOSE-UP – a favourable protocol for limb-sparing surgery of diabetic foot osteomyelitis
Introduction: Diabetic foot osteomyelitis (DFO) is a severe complication of diabetic foot ulcers, leading to high morbidity, mortality, and major limb amputation risk. While limb-sparing surgery is well established, optimal wound closure and intraosseous antibiotic strategies remain under-explored and under-reported. This study evaluates a single-stage limb-sparing surgical approach incorporating primary closure and local intraosseous antibiotic therapy. Methods: This retrospective study included 97 DFO patients (2017–2024) treated using the CLOSE-UP (Conservative surgery, Local antibiotics, Oral versus intravenous antibiotics – OVIVA, Samples, Effective limb preservation, and closUre Primary) protocol, developed to standardize DFO surgery. The one-stage procedure involved bone sampling, local debridement or minor amputation (distal to the tarsometatarsal joint), antibiotic-loaded calcium sulfate–hydroxyapatite biocomposite application, and primary wound closure. Postoperatively, patients followed the OVIVA antimicrobial protocol: 1 week of intravenous (IV) therapy and 5 weeks of oral (empiric penicillin–cloxacillin) therapy. The primary outcome was treatment failure within 1 year, with a minimum follow-up of 12 months. Results: Clinical failure occurred in 13 patients (13.4 %), with only 4 patients (4.1 %) requiring major amputation. Peripheral arterial disease was present in 24 patients (24.7 %) and was the only variable significantly associated with clinical failure (odds ratios: 10.21; PConclusions: The CLOSE-UP protocol demonstrated favourable outcomes. Given the high risk of mortality and limb loss in DFO, this structured approach has the potential to improve mobility, shorten rehabilitation, lower costs, and enhance quality of life. Further research, particularly randomized controlled trials, should focus on optimizing wound closure to improve long-term limb preservation and survival.
- 16 June 2025
- Published by Copernicus GmbH in Journal of Bone and Joint Infection
- Vol. 10 (3) , 199-206
Open AccessCLOSE-UP – a favourable protocol for limb-sparing surgery of diabetic foot osteomyelitis
Introduction: Diabetic foot osteomyelitis (DFO) is a severe complication of diabetic foot ulcers, leading to high morbidity, mortality, and major limb amputation risk. While limb-sparing surgery is well established, optimal wound closure and intraosseous antibiotic strategies remain under-explored and under-reported. This study evaluates a single-stage limb-sparing surgical approach incorporating primary closure and local intraosseous antibiotic therapy. Methods: This retrospective study included 97 DFO patients (2017–2024) treated using the CLOSE-UP (Conservative surgery, Local antibiotics, Oral versus intravenous antibiotics – OVIVA, Samples, Effective limb preservation, and closUre Primary) protocol, developed to standardize DFO surgery. The one-stage procedure involved bone sampling, local debridement or minor amputation (distal to the tarsometatarsal joint), antibiotic-loaded calcium sulfate–hydroxyapatite biocomposite application, and primary wound closure. Postoperatively, patients followed the OVIVA antimicrobial protocol: 1 week of intravenous (IV) therapy and 5 weeks of oral (empiric penicillin–cloxacillin) therapy. The primary outcome was treatment failure within 1 year, with a minimum follow-up of 12 months. Results: Clinical failure occurred in 13 patients (13.4 %), with only 4 patients (4.1 %) requiring major amputation. Peripheral arterial disease was present in 24 patients (24.7 %) and was the only variable significantly associated with clinical failure (odds ratios: 10.21; PConclusions: The CLOSE-UP protocol demonstrated favourable outcomes. Given the high risk of mortality and limb loss in DFO, this structured approach has the potential to improve mobility, shorten rehabilitation, lower costs, and enhance quality of life. Further research, particularly randomized controlled trials, should focus on optimizing wound closure to improve long-term limb preservation and survival.
- 22 November 2024
- Published by British Editorial Society of Bone & Joint Surgery in Orthopaedic Proceedings
- Vol. 106-B (SUPP_19) , 59
INVESTIGATING OSTEOLYSIS IN OSTEOMYELITIS: WHAT TO BELIEVE?
Aim: The osteolytic process of osteomyelitis is, according to textbooks, caused by increased osteoclast activity due to RANKL production by osteoblasts. However, recent findings contradict this theory. Therefore, the aim was to investigate, in a porcine osteomyelitis model, how osteolysis is affected by massive inflammation and RANKL blocking, respectively. In parallel, patients with chronic osteomyelitis, diabetes, foot osteomyelitis, and fracture related infections (FRI) were included for advanced histological analysis of osteolysis.Methods: In pigs, a tibial implant cavity was created and inoculated with 104 CFU of Staphylococcus aureus: Group A (n=7). Group B (n=7); + 1cm3 spongostan into the cavity. Group C (n=4); + systemic Denosumab treatment. Spongostan was used as an avascular material to support bacterial growth and thus increase the inflammatory response. Denosumab treatment was administrated to suppress osteoclast activity by RANKL inhibition (as in osteoporotic patients). The volume of osteolysis was accessed by CT scans. Immunohistochemistry with antibodies towards Cathepsin K was used to identify osteoclasts within the bone lesions. Briefly, the number of Cathepsin K positive cells, i.e., both precursors and bone resorbing osteoclasts, respectively, were counted in 10 high power fields (400x). In total, 50 bone infection patients were included (Herlev Hospital). From each patient five parried samples were taken for histology and microbiology, respectively. Histopathology, CT osteolysis volume estimation, and molecular expression of osteoclasts and inflammatory markers are ongoing. One FRI patient was osteoporotic and treated with Denosumab for 6 years.Results: All pigs were confirmed infected in the implant cavity. The volume (2.41 ± 1.29cm3) of osteolysis was significantly increased in the spongostan group in comparison to Group A (1.24 ± 0.59 cm3) (p=0.04). Thereby, the spongostan group had bacteria deeper into the bone from the inoculation point. Sufficient Denosumab treatment, i.e. reduced serum Ca was seen in 3 pigs. None of the Denosumab treated pigs showed reduced osteolysis in comparison to Group A (1.42 ± 0.63 cm3). The Cathepsin K score of Group C was 17 (15-23 IQR) of precursor osteoclasts and 2 (0-2 IQR) of osteoclasts in Howship lacunae. The Denosumab treated patient showed substantial osteolysis and histological analysis confirmed acute inflammatory.Conclusions: Application of spongostan, i.e., bacterial host optimization and massive inflammation promotes osteolysis and local bacterial dissemination. Osteoclast blocking with Denosumab showed no impact on osteolysis. Elucidation of the pathophysiology causing bone loss in osteomyelitis is fundamental. However, the widely accepted osteoclast-based theory might not be the only relevant.
- 22 November 2024
- Published by British Editorial Society of Bone & Joint Surgery in Orthopaedic Proceedings
- Vol. 106-B (SUPP_19) , 59
INVESTIGATING OSTEOLYSIS IN OSTEOMYELITIS: WHAT TO BELIEVE?
Aim: The osteolytic process of osteomyelitis is, according to textbooks, caused by increased osteoclast activity due to RANKL production by osteoblasts. However, recent findings contradict this theory. Therefore, the aim was to investigate, in a porcine osteomyelitis model, how osteolysis is affected by massive inflammation and RANKL blocking, respectively. In parallel, patients with chronic osteomyelitis, diabetes, foot osteomyelitis, and fracture related infections (FRI) were included for advanced histological analysis of osteolysis.Methods: In pigs, a tibial implant cavity was created and inoculated with 104 CFU of Staphylococcus aureus: Group A (n=7). Group B (n=7); + 1cm3 spongostan into the cavity. Group C (n=4); + systemic Denosumab treatment. Spongostan was used as an avascular material to support bacterial growth and thus increase the inflammatory response. Denosumab treatment was administrated to suppress osteoclast activity by RANKL inhibition (as in osteoporotic patients). The volume of osteolysis was accessed by CT scans. Immunohistochemistry with antibodies towards Cathepsin K was used to identify osteoclasts within the bone lesions. Briefly, the number of Cathepsin K positive cells, i.e., both precursors and bone resorbing osteoclasts, respectively, were counted in 10 high power fields (400x). In total, 50 bone infection patients were included (Herlev Hospital). From each patient five parried samples were taken for histology and microbiology, respectively. Histopathology, CT osteolysis volume estimation, and molecular expression of osteoclasts and inflammatory markers are ongoing. One FRI patient was osteoporotic and treated with Denosumab for 6 years.Results: All pigs were confirmed infected in the implant cavity. The volume (2.41 ± 1.29cm3) of osteolysis was significantly increased in the spongostan group in comparison to Group A (1.24 ± 0.59 cm3) (p=0.04). Thereby, the spongostan group had bacteria deeper into the bone from the inoculation point. Sufficient Denosumab treatment, i.e. reduced serum Ca was seen in 3 pigs. None of the Denosumab treated pigs showed reduced osteolysis in comparison to Group A (1.42 ± 0.63 cm3). The Cathepsin K score of Group C was 17 (15-23 IQR) of precursor osteoclasts and 2 (0-2 IQR) of osteoclasts in Howship lacunae. The Denosumab treated patient showed substantial osteolysis and histological analysis confirmed acute inflammatory.Conclusions: Application of spongostan, i.e., bacterial host optimization and massive inflammation promotes osteolysis and local bacterial dissemination. Osteoclast blocking with Denosumab showed no impact on osteolysis. Elucidation of the pathophysiology causing bone loss in osteomyelitis is fundamental. However, the widely accepted osteoclast-based theory might not be the only relevant.